Stock Events

Stock Events

Lakefront Biotherapeutics NV 

$27.45
234
-$0.32-1.15% Friday 19:54

Statistics

Day High
27.99
Day Low
27.44
52W High
37.62
52W Low
26.61
Volume
123,617
Avg. Volume
-
Mkt Cap
1.81B
P/E Ratio
3.18
Dividend Yield
-
Dividend
-

Upcoming

Earnings

10AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-3.6
-2.3
-1
0.3
Expected EPS
-0.81220184
Actual EPS
N/A

Financials

-2.62%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
3.02BRevenue
-79.04MNet Income

Analyst Ratings

33Average Price Target
The highest estimate is 33.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GLPG. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.28B
Vertex Pharmaceuticals is a direct competitor in the cystic fibrosis market, where both companies are developing treatments.
Gilead Sciences
GILD
Mkt Cap166.82B
Gilead Sciences collaborates with Galapagos on filgotinib but also competes in other areas of biopharmaceuticals, including antiviral drugs.
Abbvie
ABBV
Mkt Cap381.1B
AbbVie competes in the immunology space, particularly in treatments for rheumatoid arthritis, where Galapagos also has interests.
AMGEN
AMGN
Mkt Cap183.12B
Amgen competes in the biotech space, focusing on innovative therapeutics, including areas like inflammation where Galapagos is active.
Regeneron Pharmaceuticals
REGN
Mkt Cap66.98B
Regeneron Pharmaceuticals is involved in developing treatments for conditions like asthma and arthritis, directly competing with Galapagos' pipeline.
Biogen
BIIB
Mkt Cap28.61B
Biogen competes in the area of biopharmaceuticals with a focus on neurodegenerative diseases, an area Galapagos has shown interest in.
Novartis
NVS
Mkt Cap290.05B
Novartis competes across a broad range of therapeutic areas, including those targeted by Galapagos, such as autoimmune diseases.
Pfizer
PFE
Mkt Cap147.62B
Pfizer operates in various therapeutic areas, including inflammation and immunology, competing with Galapagos' research and development efforts.
Merck
MRK
Mkt Cap302.33B
Merck & Co. competes in the pharmaceutical and biotech sectors, focusing on innovative treatments that could overlap with Galapagos' interests.
Astrazeneca
AZN
Mkt Cap290.06B
AstraZeneca competes in multiple areas, including respiratory diseases, where Galapagos also focuses its research efforts.

About

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Show more...
CEO
Mr. Henry Gosebruch
Employees
704
Country
Belgium
ISIN
US36315X1019

Listings

MU
DE
GXE.MU
STU
DE
GXE.STU
XETRA
DE
GXE.XETRA
BR
BE
GLPG.BR

0 Comments

Share your thoughts

FAQ

What is Lakefront Biotherapeutics NV stock price today?▼
The current price of GLPG is $27.45 USD — it has decreased by -1.15% in the past 24 hours. Watch Lakefront Biotherapeutics NV stock price performance more closely on the chart.
What is Lakefront Biotherapeutics NV stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Lakefront Biotherapeutics NV stocks are traded under the ticker GLPG.
Is Lakefront Biotherapeutics NV stock price growing?▼
GLPG stock has risen by +3.16% compared to the previous week, the month change is a -4.02% fall, over the last year Lakefront Biotherapeutics NV has showed a -4.46% decrease.
What is Lakefront Biotherapeutics NV market cap?▼
Today Lakefront Biotherapeutics NV has the market capitalization of 1.81B
When is the next Lakefront Biotherapeutics NV earnings date?▼
Lakefront Biotherapeutics NV is going to release the next earnings report on August 10, 2026.
What were Lakefront Biotherapeutics NV earnings last quarter?▼
GLPG earnings for the last quarter are 0.24 USD per share, whereas the estimation was -0.94 USD resulting in a +125.77% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Lakefront Biotherapeutics NV revenue for the last year?▼
Lakefront Biotherapeutics NV revenue for the last year amounts to 3.02B USD.
What is Lakefront Biotherapeutics NV net income for the last year?▼
GLPG net income for the last year is -79.04M USD.
How many employees does Lakefront Biotherapeutics NV have?▼
As of May 26, 2026, the company has 704 employees.
In which sector is Lakefront Biotherapeutics NV located?▼
Lakefront Biotherapeutics NV operates in the Health & Wellness sector.
When did Lakefront Biotherapeutics NV complete a stock split?▼
Lakefront Biotherapeutics NV has not had any recent stock splits.
Where is Lakefront Biotherapeutics NV headquartered?▼
Lakefront Biotherapeutics NV is headquartered in Mechelen, Belgium.